[
    "{\"step_by_step_thinking\": \"Based on the information provided in the relevant documents, AZD3759 is described as an EGFR tyrosine kinase inhibitor with good blood-brain barrier (BBB) penetration. Document [0] states that AZD3759 has excellent BBB penetration, and Document [3] mentions that AZD3759 can fully penetrate the BBB, with equal free concentrations in the blood, cerebrospinal fluid, and brain tissue. Additionally, Document [6] discusses the molecular dynamics simulations of AZD3759 with a lipid bilayer, indicating that AZD3759 prefers to reside in the interface between the hydrophilic headgroup region and hydrophobic region of the bilayer, suggesting its ability to cross the BBB. Therefore, the answer is A. yes, AZD3759 crosses the blood brain barrier.\", \"answer_choice\": \"A\"}"
]